中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2010年
10期
835-838
,共4页
碘同位素%治疗%分化型甲状腺癌
碘同位素%治療%分化型甲狀腺癌
전동위소%치료%분화형갑상선암
Iodine isotopes%Therapy%Differentiated thyroid carcinoma
甲状腺癌为最常见的内分泌肿瘤,甲状腺癌组织类型主要为分化型甲状腺癌,手术+131I+甲状腺素抑制模式治疗分化型甲状腺癌久已得到认可和广泛应用.本文简要介绍131I治疗分化型甲状腺癌的现状并略加评述.
甲狀腺癌為最常見的內分泌腫瘤,甲狀腺癌組織類型主要為分化型甲狀腺癌,手術+131I+甲狀腺素抑製模式治療分化型甲狀腺癌久已得到認可和廣汎應用.本文簡要介紹131I治療分化型甲狀腺癌的現狀併略加評述.
갑상선암위최상견적내분비종류,갑상선암조직류형주요위분화형갑상선암,수술+131I+갑상선소억제모식치료분화형갑상선암구이득도인가화엄범응용.본문간요개소131I치료분화형갑상선암적현상병략가평술.
Thyroid cancer is the most frequent endocrine malignancy. The histologic subtype of thyroid carcinoma is mainly differentiated thyroid carcinoma. The treatment modality of thyroidectomy followed by 131I and thyroxine-suppressive therapy has been approved and applied widely. A brief introduction and a commentary on this topic is presented in this article.
